Immune recall enhances cross-reactive antibody longevity after a large wave of SARS-CoV-2 breakthrough infection

Dan Li, Qingfei Chu, Shuo Li, Lanjuan Li, Yiming ShaoSignal 2024 · DOI · OpenAlex

Abstract

As SARS-CoV-2 transitions from a global emergency to an endemic state, the landscape of human immunity has become increasingly complex due to vaccination, natural infection, and the emergence of novel variants. This study investigates the cross-reactivity and longevity of humoral immunity in individuals who experienced breakthrough infections (BTI) with Omicron BA.5/BF.7 variants. By tracking a cohort of 59 participants over six months, we demonstrate that breakthrough infections—particularly those with moderate symptoms—trigger a robust "immune recall" that enhances the breadth and durability of neutralizing antibodies against future variants, including JN.1 and KP.2. Our findings suggest that pre-existing seasonal coronavirus immunity and repeated exposures significantly broaden the protective reach of the immune system.

Introduction

The global transmission dynamics of SARS-CoV-2 are now defined by "hybrid immunity," a combination of vaccine-induced protection and multiple infection events. A critical question for public health is how exposure to one variant prepares the immune system for future, genetically distant mutations. This study explores the role of "immune recall" versus "original antigenic sin" in shaping the long-term antibody response after the large wave of Omicron infections in China.

Methods

The researchers conducted a longitudinal study following 59 participants (average age 34) in China. The cohort consisted of 50 convalescent COVID-19 patients (40 mild, 10 moderate) and 9 SARS-CoV-2 naïve controls. Notably, 97% of participants had received inactivated vaccines (BBIBP-CorV or CoronaVac).

Antibody responses were evaluated at 1, 3, and 6 months post-recovery using Pseudovirus Neutralization Tests (PVNT) against nine strains: the Prototype virus and Omicron variants BA.1, BA.2, BA.4/5/5.2, BF.7, XBB, EG.5, JN.1, and KP.2. Additionally, ELISA assays measured binding IgG levels against SARS-CoV-2 proteins and four seasonal coronaviruses (HCoV-OC43, HKU1, NL63, and 229E).

Figure 1: Study design and longitudinal analysis of neutralizing antibody responses across various SARS-CoV-2 variants.

Key Insights and Results

Severity and Durability

Clinical severity was a significant predictor of antibody longevity. Patients with moderate symptoms (respiratory involvement) maintained higher geometric mean titers (GMT) of neutralizing antibodies (nAbs) compared to those with mild symptoms. While nAb levels generally declined over six months, the moderate group showed a more resilient "memory" response across all tested variants.

Cross-Reactivity and the "Evolutionary Branch Rule"

Despite being infected with BA.5/BF.7, participants developed measurable neutralization against newer variants like JN.1 and KP.2. The data suggests an "evolutionary branch rule": exposure to a variant on a specific lineage allows the immune system to more effectively recognize future mutations within that same branch.

The Impact of Re-infection

During the six-month follow-up, 15 participants experienced a second breakthrough infection (likely XBB). These individuals exhibited a dramatic increase in nAbs across the entire variant spectrum. This "re-infection boost" significantly broadened the immune response, providing higher protection against the latest variants compared to those with only a single infection event.

Figure 2: GMT line chart showing the significant boost in neutralizing antibody titers against all variants following re-infection.

Seasonal Coronavirus Synergy

An intriguing finding was the positive correlation between HCoV-OC43 (common cold) antibodies and SARS-CoV-2 nAbs. This suggests that pre-existing immunity to seasonal coronaviruses may synergize with the COVID-19 response, potentially acting as a foundation for broader cross-reactive memory.

Discussion and Limitations

This study highlights the potency of immune recall in vaccinated individuals. Breakthrough infections act as a natural booster, training the immune system to recognize diverse viral features. However, the study is limited by a small sample size (n=59) and the lack of baseline seasonal coronavirus data prior to infection. Future research should investigate the role of T-cell immunity and larger, more diverse cohorts to further refine our understanding of long-term hybrid immunity.

Summary updated

Abstract

Although coronavirus disease 2019 (COVID-19) is no longer deemed a "Public Health Emergency of International Concern", the global transmission dynamics of SARS-CoV-2 have shifted due to vaccination, emergency of virus variants, and pre-existing coronavirus immunity. 1-3It remains unclear how cross-reactive and pre-existing humoral immunity might impact the effectiveness of vaccines and antibodies against new viral mutations. 4,5 This study seeks to elucidate the cross-reactivity of coronavirus antibodies induced by previously unencountered Omicron BA.5/ BF.7 variants in the breakthrough infection (BTI) population.We enrolled 59 participants, with an average age of 34 (range: 22-67) years, comprising 42% males.Notably, 97% of people have received the inactivated COVID-19 vaccine (BBIBP-CorV or CoronaVac), of which 54% have received booster shots (third or even fourth doses).The cohort consisted of 50 patients with convalescent COVID-19 (40 with mild symptoms, 10 with moderate symptoms) and 9 SARS-CoV-2 nave controls (who were all vaccinated but had not been infected when they were first recruited) (Fig. 1a).Moderate individuals exhibited more respiratory symptoms, while those with mild cases experienced predominantly gastrointestinal issues.In our cohort, most infections (from December 2022 to January 2023) were presumed to be the Omicron-BA.5/BF.7 strain, based on prevailing variants in China.We investigated antibody responses in individuals recovering from mild and moderate COVID-19, as well as a SARS-CoV-2 nave control group, over 1, 3, and 6 months postrecovery.Using pseudovirus neutralization test (PVNT), we assessed neutralizing antibodies (nAbs) against nine SARS-CoV-2 strains: Prototype (PT), and Omicron variants (BA.1, BA.2, BA.4/5/5.2,BF.7, XBB, EG.5, JN.1 and KP.2).Post-recovery patients, irrespective of COVID-19 severity, maintained elevated levels of nAbs compared with SARS-CoV-2 nave controls at both 3 and 6 months.Overall, the antibody level of moderate cases was higher than that of mild cases, but there was no statistical difference except for the nAbs level of JN.1 at three months of recovery.We may attribute it to the small sample size of this study.The geometric mean titre (GMT) line chart also showed a slightly higher nAbs level in moderate cases (Fig. 1b).Intriguingly, for XBB, EG.5, JN.1 and KP.2 variants, emerging after BF.7, participants displayed relatively lower nAb levels.It was worth mentioning that through the 6-months follow-up study on the unexposed variants, though JN.1 and KP.2 are recently emerged strains, we observed relatively higher levels of nAbs of these two variants than that of the previous XBB and EG.5 at the three-month recovery after COVID-19.But at the six-month follow-up time points, in the re-infected donors, despite nAbs to all tested strains were increased, the response to XBB and EG.5 were stronger than JN.1 and KP.2 which may due to the XBB epidemics in China between the two followup time points.The most probably reason for this phenomenon
BibTeX
@inproceedings{li2024immune,
  author = {Dan Li and Qingfei Chu and Shuo Li and Lanjuan Li and Yiming Shao},
  title = {{Immune recall enhances cross-reactive antibody longevity after a large wave of SARS-CoV-2 breakthrough infection}},
  booktitle = {Signal},
  year = {2024},
  doi = {10.1038/s41392-024-01926-w},
}
Figure